Abraxane (Celgene Oncology) success in Phase II study for Metastatic Melanoma

A Phase III, randomized, international study (CA033) reported for Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound), from Celgene Oncology, in chemotherapy-na�ve patients with Metastatic Melanoma. In the study, the primary endpoint was met with patients receiving Abraxane demonstrating a statistically significant improvement in progression-free survival compared to patients receiving dacarbazine (DTIC) chemotherapy. The safety profile of Abraxane observed in the CA033 study is consistent with other Abraxane pivotal clinical trials. Data from this study will be presented at the Society for Melanoma Research (SMR) Congress 2012 in Los Angeles in November 2012.